NASDAQ$EXAS

Exact Sciences Corp · Q4 2021 earnings

Q4 2021 earnings · · Investor relations

Briefing

Exact Sciences' financial performance remained steady with revenue growth, driven by Screening and Precision Oncology segments, despite a decrease in COVID-19 testing revenue.

Exact Sciences reported Q4 2021 revenue of $473.8 million, a 2% increase compared to Q4 2020. Screening revenue increased by 11%, and Precision Oncology revenue increased by 27%. The company's net loss was $220.6 million, an improvement compared to the net loss of $418.3 million in the same period of the previous year.

  • Total revenue for Q4 2021 was $473.8 million, a 2% increase year-over-year.
  • Screening revenue reached $277.7 million, an 11% increase year-over-year.
  • Precision Oncology revenue was $149.0 million, a 27% increase year-over-year.
  • COVID-19 testing revenue decreased by 52% to $47.1 million.

Headline financials

Total Revenue

$474M

Previous: $466M+1.6%
EPS (adj)

-$1.28

Previous: -$0.15-753.3%
Gross Margin

70.0%

Previous: 74.0%-5.4%
Adjusted Gross Margin

75.0%

Previous: 79.0%-5.1%
Adjusted EBITDA

-$122M

Previous: $87.9M-239.0%
Capital Expenditures

$59.4M

Previous: $16.6M+258.4%
Free Cash Flow

-$84M

Previous: $94.8M-188.5%
Net Income

-$221M

Previous: -$437M+49.5%
Operating Income

-$221M

Previous: -$415M+46.7%
Gross Profit

$334M

Previous: $346M-3.6%
Cash & Equivalents

$315M

Previous: $1.49B-78.8%
Total Assets

$6.68B

Previous: $4.93B+35.7%
Stock-Based Comp

$55.9M

Previous: $41.8M+33.6%

Revenue & EPS history

Exact Sciences · Revenue · Quarterly

$474M

Q4 2021+1.6%vs Q4 2020
Beat estimate in 11 of 16 quarters(69%)
ActualEstimate

Revenue by segment

Exact Sciences · $427M total across 2 segments · Q4 2021

  • Screening
    $278M+11.2%
  • Precision Oncology
    $149M+26.7%

Forward guidance

The company anticipates revenue of $1.975-$2.027 billion during 2022.

Tailwinds

  • Screening revenue of $1.340-$1.367 billion, including $40-$42 million from PreventionGenetics
  • Precision Oncology revenue of $595-$610 million
  • COVID-19 testing revenue of $40-$50 million
  • Strong momentum from the fourth quarter carrying over to the new year
  • Team of talented people dedicated to defeating cancer

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 18 quarterly earnings reports · overlaid with Q4 2021

Historical avgQ4 2021

+0.8%

Avg return

Earnings day

+2.3%

Avg return

5 days after

+3.4%

Avg return

30 days after

55%

35 / 64 earnings

Positive

+35.0%

Q2 2016

Best reaction

-27.1%

Q3 2010

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026
Q4 2025+0.0%+0.0%+0.7%
Q3 2025+3.8%-1.2%+51.0%
Q2 2025-8.2%-11.0%+14.7%
Q1 2025+9.1%+13.0%+19.3%
Q4 2024-1.9%-0.6%-9.6%
Q3 2024-23.1%-27.6%-12.0%
Q2 2024+24.3%+19.7%+32.4%
Q1 2024-11.8%-9.5%-30.1%
Q4 2023-5.2%-8.3%-1.0%
Q3 2023+1.4%+5.9%+8.8%
Q2 2023-12.7%-12.6%-14.2%
Q1 2023+14.9%+15.5%+32.2%
Q4 2022+1.9%-5.4%+3.0%
Q3 2022+13.8%+23.9%+40.4%
Q2 2022+0.8%-0.3%-23.2%
Q1 2022-0.2%-12.1%-20.4%
Q4 2021-6.9%+5.7%-9.5%
Q3 2021-3.2%+3.3%-17.3%
Q2 2021-0.0%-3.2%-7.2%
Q1 2021-11.9%-16.8%-14.0%
Q4 2020-9.0%-4.6%-17.4%
Q3 2020+19.7%+16.2%+8.7%
Q2 2020+0.1%-1.8%-22.7%
Q1 2020+6.3%+7.7%+11.3%
Q4 2019-1.1%+1.4%-46.8%
Q3 2019-9.5%-3.1%-12.2%
Q2 2019-0.0%-2.4%+1.9%
Q1 2019-0.9%+6.7%+3.5%
Q4 2018+10.1%+10.7%+6.4%
Q3 2018+15.5%+20.7%+23.3%
Q2 2018-11.7%-12.9%+28.1%
Q1 2018+14.9%+10.5%+14.5%
Q4 2017-9.2%-4.9%-5.4%
Q3 2017+7.5%+10.8%+13.0%
Q2 2017+0.5%+0.1%+4.2%
Q1 2017+26.1%+30.1%+40.0%
Q4 2016+14.0%+7.6%+2.9%
Q3 2016-22.1%-20.5%-19.3%
Q2 2016+35.0%+39.5%+52.9%
Q1 2016-16.9%
Q4 2015-9.5%
Q3 2015+1.0%
Q2 2015-8.9%
Q1 2015+6.2%
Q4 2014-0.8%
Q3 2014+6.1%
Q2 2014+1.1%
Q1 2014+0.7%
Q4 2013+10.5%
Q3 2013-1.0%
Q2 2013-8.0%
Q1 2013+2.4%
Q4 2012+2.7%
Q3 2012+5.4%
Q2 2012+5.4%
Q1 2012+1.4%
Q4 2011+4.6%
Q3 2011-4.1%
Q2 2011-6.7%
Q1 2011+1.6%
Q4 2010+2.8%
Q3 2010-27.1%
Q2 2010+3.3%
Q1 2010+6.0%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro